Price to earnings forward of Bicara Therapeutics Inc. – NASDAQ:BCAX
This article displays financial data for Bicara Therapeutics Inc. (NASDAQ: BCAX), specifically focusing on its Price to Earnings (P/E) forward ratio. The content is primarily a data display from TradingView, indicating that specific financial metrics are available for the company.
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced that it awarded inducement grants to four new employees on July 1, 2026, under its 2026 Inducement Plan. These grants, comprising non-qualified stock options to purchase 191,425 shares of common stock, were made as a material inducement for their employment. The awards were approved by the compensation committee and are in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced that it awarded inducement grants to four new employees on July 1, 2026, under its 2026 Inducement Plan. These grants consisted of non-qualified stock options to purchase 191,425 shares of Bicara’s common stock at an exercise price of $28.91 per share. The awards were approved by the compensation committee of Bicara’s board of directors, aligning with Nasdaq Listing Rule 5635(c)(4).
Citizens upgrades Bicara Therapeutics stock price target on CRC data
Citizens has reaffirmed a Market Outperform rating and a $31.00 price target for Bicara Therapeutics Inc. (NASDAQ: BCAX) following strong preclinical data for its drug ficera in metastatic colorectal cancer (CRC). Despite trading near its 52-week high, the stock appears overvalued according to InvestingPro analysis, though the company maintains a strong balance sheet. The firm anticipates further clinical presentations for ficera, noting its potential to address a high unmet need in late-line metastatic CRC.
BCAX - Bicara Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Bicara Therapeutics Inc (BCAX), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key statistics such as EPS, insider and institutional ownership, profitability margins, and stock performance metrics over different periods. The data covers volatility, Greeks (though specific Greek values are not provided in the text), and compares BCAX with its peers in the healthcare biotechnology sector.
Bicara Therapeutics Inc. Actuals & Estimates (BOATS:BCAX)
This article provides an overview of Bicara Therapeutics Inc. (BCAX) stock, covering its financial actuals and estimates as traded on the BOATS exchange. It includes analyst forecasts, historical price data, upcoming earnings dates, recent financial results such as EPS and revenue, and company details like employee count. The article also addresses frequently asked questions regarding BCAX stock.
Bicara Therapeutics Inc. Actuals & Estimates (NASDAQ:BCAX)
This article provides financial actuals and estimates for Bicara Therapeutics Inc. (NASDAQ:BCAX), including its current stock price, market capitalization, and volatility. It also details analyst price targets, past performance, future earnings forecasts, and highlights that the company does not pay dividends.
Form 144 BICARA THERAPEUTICS INC. For: 25 June By Investing.com
This article reports on the Form 144 filing for BICARA THERAPEUTICS INC. dated June 25. It emphasizes the risks associated with trading financial instruments and cryptocurrencies, including volatility and potential loss of investment. Investing.com reminds users that data may not be real-time or accurate and advises seeking professional advice before trading.
Form 144 BICARA THERAPEUTICS INC. For: 25 June By Investing.com
This article announces that BICARA THERAPEUTICS INC. filed a Form 144 for June 25. The brief report from Investing.com provides no additional details beyond the filing date.
Form 144 BICARA THERAPEUTICS INC. For: 25 June By Investing.com
This article announces the filing of Form 144 for BICARA THERAPEUTICS INC. on June 25th, published by Investing.com. It indicates a financial transaction related to the company, highlighted within the stock market news section. The document is crucial for investors tracking insider sales or affiliates' intent to sell restricted or controlled securities.
BCAX (NASDAQ: BCAX) affiliate to offer 50,000 shares after option exercise
An affiliate of BCAX (NASDAQ: BCAX) has filed a Form 144 to sell 50,000 shares, which will result from a stock option exercise to be settled for cash. The aggregate offering value is stated as $1,324,650.00. The filing also reports two prior sales by the same affiliate, totaling 5,500 shares each on May 26, 2026, and April 27, 2026.
BCAX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Bicara Therapeutics Inc. (BCAX), highlighting current stock performance, analyst opinions, financial data, and future earnings estimates. It includes a summary of recent stock movements, historical high and low prices, market capitalization, and volatility.
Bicara Therapeutics Inc (BCAX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Bicara Therapeutics Inc (BCAX), highlighting analyst ratings and EPS expectations. Based on 15 analysts, the stock has a "Buy" rating with a target price indicating a 37.27% upside. The report details past EPS performance and future forecasts, noting an expected EPS of USD -0.83 for the next quarter.
Bicara Therapeutics Inc (BCAX) Institutional Confidence
This article provides details on the institutional confidence in Bicara Therapeutics Inc (BCAX), highlighting key shareholders and changes in their holdings. The report lists major institutional investors like RA Capital Management, T. Rowe Price Investment Management, and Biocon Ltd., along with their share counts and percentage changes. It serves as part of a broader stock analysis by TradingKey, focusing on institutional activity.
Bicara Therapeutics Inc (BCAX) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Bicara Therapeutics Inc (BCAX), focusing on metrics like P/E, P/B, P/S, and P/CF. However, it states that relevant data for these valuation ratios have not yet been disclosed by the company. The page also includes basic stock information such as its current price, market cap, and links to other financial tools and analyses.
Bicara Therapeutics Inc (BCAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Bicara Therapeutics Inc (BCAX) by business segments and regional contributions. However, it explicitly states that the relevant data for revenue breakdown has not yet been disclosed by the company, both for business segments and by region. The page provides general company information such as market cap and stock performance but lacks the specific financial details implied by the title.
Director Kate Haviland awarded 19,475 Bicara (BCAX) stock options at $20.56
Bicara Therapeutics Inc. director Kate Haviland was granted 19,475 stock options at an exercise price of $20.56 per share as compensation. These options are not an open-market purchase and will vest on the earlier of June 9, 2027, or the next Annual Meeting of Stockholders, contingent on her continued service. Following this grant, her total reported option holdings from this award amount to 19,475 shares.
Form 4] Bicara Therapeutics Inc. Insider Trading Activity
Bicara Therapeutics Inc. director Christopher Bowden reported a new stock option grant, receiving options to buy 19,475 shares at an exercise price of $20.56 per share, expiring in 2036. The options vest by June 9, 2027, or the next Annual Meeting of Stockholders. Following this, Bowden directly holds stock options covering 19,475 shares.
Bicara Therapeutics (BCAX) director receives 19,475-share option tied to RA Capital
Bicara Therapeutics Inc. director Jake Simson was granted a stock option for 19,475 shares of BCAX stock with an exercise price of $20.56, set to expire on June 9, 2036. This compensation-related grant is tied to RA Capital, as any net proceeds from the option's exercise will be turned over to RA Capital Healthcare Fund LP and RA Capital Nexus Fund III LP to offset advisory fees. The option vests on the earlier of June 9, 2027, or the next annual stockholders’ meeting, contingent on Simson’s continued service.
[Form 4] Bicara Therapeutics Inc. Insider Trading Activity
Bicara Therapeutics Inc. director Jake Simson was granted 19,475 stock options at an exercise price of $20.56 per share. These options are held for the benefit of R.A. Capital Healthcare Fund and R.A. Capital Nexus Fund III, with Simson disclaiming beneficial ownership, and are considered routine equity compensation rather than a market transaction. The options vest on the earlier of June 9, 2027, or the next Annual Meeting of Stockholders, contingent on Simson's continued service.
[8-K] Bicara Therapeutics Inc. Reports Material Event
Bicara Therapeutics Inc. held its 2026 annual meeting on June 9, 2026, where stockholders elected Christopher Bowden, M.D., and Carolyn Ng, Ph.D., as Class II directors. They also ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Approximately 85.25% of the outstanding common shares were represented at the meeting, and both proposals passed with significant support.
A Look At Bicara Therapeutics (BCAX) Valuation After New Ficerafusp Alfa Survival Data And Phase 3 Progress
Bicara Therapeutics (BCAX) released promising three-year follow-up data for its lead candidate, ficerafusp alfa, in head and neck cancer, leading to significant share price momentum. Despite recent short-term dips, the stock has shown strong year-to-date and one-year returns. Valued at US$1.29 billion, Bicara trades at a discount to analyst price targets, with differing valuation models (narrative-based and DCF) both suggesting potential upside.
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating
Cantor Fitzgerald has reiterated an Overweight rating on Bicara Therapeutics Inc (NASDAQ: BCAX), noting the stock's significant return over the past year. Analysts maintain varied price targets, and a consultant specializing in head and neck cancer treatments believes Bicara's ficerafusp, alongside Genmab’s petosemtamab and Johnson & Johnson’s amivantamab, will likely be approved and adopted, with Bicara potentially benefiting from the best Phase 3 trial design. Despite missing Q1 2026 earnings, Bicara highlighted its strong cash position and clinical progress, including encouraging survival data from a study of ficerafusp alfa combined with pembrolizumab.
Bicara (BCAX) Q4 2025 Earnings Transcript
Bicara Therapeutics (BCAX) held its first quarterly earnings call for Q4 2025, highlighting its lead asset FICERA, which received FDA breakthrough therapy designation for HPV-negative head and neck cancer. The company presented positive Phase Ib data demonstrating deep, durable responses and significant overall survival approaching 22 months in some cohorts. Bicara also announced plans for a more flexible maintenance dosing schedule and confirmed a strong financial position with a cash runway extending into the first half of 2029, supporting ongoing pivotal trials and commercial buildout.
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Bicara Therapeutics (NASDAQ: BCAX) after a meeting with management, noting the strong market performance of its stock, up 34% year-to-date. The firm views Bicara's ficerafusp as a potential best-in-class drug despite the company falling short of Q1 2026 earnings expectations. Other analysts have also reiterated positive ratings and price targets, highlighting ongoing clinical trial progress.
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating By Investing.com
Cantor Fitzgerald reiterated an "Overweight" rating on Bicara Therapeutics (NASDAQ:BCAX) after a recent meeting with management. The firm believes Ficerafusp, Bicara's lead product, has the potential to be a best-in-class drug for HPV-negative head and neck squamous cell carcinoma, with its stock up 34% year-to-date and 120% over the past year. Despite a recent earnings miss, the company maintains a strong cash position and continues to progress in clinical trials, with analysts setting price targets ranging from $16 to $46.
Bicara Therapeutics CFO Ivan Hyep sells $187,883 in stock
Bicara Therapeutics CFO Ivan Hyep sold 9,200 shares of the company's common stock for $187,883 on May 21, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan and occurred after Hyep exercised stock options to acquire the same number of shares. This insider transaction follows recent Q1 2026 financial results that missed analyst expectations, although the company highlighted its strong cash position and clinical trial progress for FICERA.
BCAX (Nasdaq: BCAX) insider notice: 5,500 shares tied to option exercise
Bicara Therapeutics Inc. (BCAX) has filed a Form 144 indicating a proposed sale of 5,500 shares of common stock, stemming from an option exercise dated May 26, 2026. This filing, which is a notice of intent to sell rather than a confirmation of sale, also details several past sales by David Raben between March and April 2026. The transaction is listed with a neutral impact and sentiment, involving cash settlement.
Cantor Fitzgerald reiterates Bicara Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Bicara Therapeutics (NASDAQ:BCAX) after a meeting with senior management, following a positive clinical update on their ficerafusp antibody. Despite the stock being up 34% year-to-date and 120% over the past year, InvestingPro data suggests it might be overvalued. The firm views ficerafusp as a potential best-in-class drug for HPV-negative head and neck squamous cell carcinoma, highlighting its competitive positioning against other treatments.
BCAX Technical Analysis | Trend, Signals & Chart Patterns | BICARA THERAPEUTICS INC (NASDAQ:BCAX)
This article provides a technical analysis of BICARA THERAPEUTICS INC (NASDAQ:BCAX), assigning it a strong technical rating of 9 out of 10. It highlights the stock's positive long-term trend, outperformance against its industry peers and the broader market, and identifies key support and resistance levels. Despite a medium setup quality due to recent volatility, various indicators suggest a generally positive outlook, though the MACD indicates a bearish trend.
Bicara Therapeutics CFO Ivan Hyep sells $187,883 in stock
Bicara Therapeutics CFO Ivan Hyep sold 9,200 shares of the company's common stock for $187,883 on May 21, 2026, after acquiring them through stock option exercises on the same day. The transactions were part of a pre-arranged Rule 10b5-1 trading plan. Following the sale, Hyep holds 145,355 shares and 70,584 stock options, while BCAX shares have seen a 137% increase over the past year.
A Look At Bicara Therapeutics (BCAX) Valuation After New Ficerafusp Alfa Head And Neck Cancer Data
Bicara Therapeutics (BCAX) received renewed investor attention following the release of three-year follow-up data for ficerafusp alfa in HPV-negative head and neck cancer, leading to a recent share price surge. Despite this positive momentum, the company's valuation, at US$21.68 against an analyst target of US$31.46, raises questions about whether its potential is fully priced in, as its fair value estimate of $30.50 is based largely on a single asset and optimistic long-term revenue forecasts. While the narrative suggests undervaluation, it also highlights significant risks if the lead asset's trial faces setbacks or market uptake is slower than anticipated.
Bicara Therapeutics (BCAX) CFO sells 9,200 shares after exercising options
Bicara Therapeutics' CFO, Hyep Ivan, sold 9,200 shares of common stock at a weighted average price of $20.4221 per share after exercising options at $3.7898 per share. This transaction, executed on May 21, 2026, was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following the sale, Ivan directly holds 145,355 shares and retains options for an additional 70,584 shares.
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Therapeutics Inc. announced extended three-year follow-up data from its Phase 1/1b study of ficerafusp alfa in combination with pembrolizumab for first-line recurrent/metastatic HPV-negative head and neck squamous cell carcinoma (HNSCC). The data showed deep, durable responses and significant overall survival benefits, approximately doubling the survival rate compared to standard of care, with a generally well-tolerated safety profile. The company attributes these positive results to TGF-β inhibition, noting that deep responses translated into durable long-term outcomes for patients.
Bicara Therapeutics: 1500mg Ficerafusp Alfa + Pembrolizumab Shows Estimated 31% 3‑Year OS in 1L R/M HPV‑Negative HNSCC
Bicara Therapeutics announced that a combination of 1500mg weekly ficerafusp alfa and pembrolizumab demonstrated an estimated 31% overall survival at three years in patients with 1L R/M HPV-Negative HNSCC, approximately double the retrospective standard-of-care with pembrolizumab alone. The treatment showed deep, durable responses driven by TGF-β inhibition, with increasing complete response rates and deep response percentages across higher ficerafusp alfa dosages. The company is advancing with a Phase 3 study and planning a future maintenance regimen.
Bicara Therapeutics (BCAX) CEO sells 15K shares and exercises options
Bicara Therapeutics Inc.'s CEO, Claire Mazumdar, sold 15,000 shares of common stock at an average price around $20 per share and simultaneously exercised options to acquire 15,000 shares at $3.7898 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. Following these moves, Mazumdar still directly holds 377,152 shares of common stock and retains options for an additional 146,107 shares, indicating continued significant equity exposure.
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock
Bicara Therapeutics' President and COO, Ryan Cohlhepp, sold 12,500 shares for over $253,000 but also acquired 8,000 shares through stock options. These transactions, executed under a 10b5-1 plan, occurred as the company's stock declined 11.7% in a week, though it remains up nearly 30% over six months. Analysts maintained positive ratings while the company reported missing EPS expectations but highlighted strong cash reserves and clinical trial progress for FICERA.
Bicara Therapeutics Inc. - Common Stock (Nasdaq:BCAX) Stock Quote
This article provides a stock quote and recent news for Bicara Therapeutics Inc. (Nasdaq: BCAX). It highlights the current stock price, recent performance metrics, and a list of news headlines, including financial results, insider filings, and business updates related to the company's oncology drug development.
Vestal Point and Ryan Wilder disclose 8.3% Bicara stake (BCAX)
Vestal Point Capital, LP and Ryan Wilder have reported a beneficial ownership of 5,425,000 shares, equating to an 8.3% stake in Bicara Therapeutics (BCAX), based on 65,467,187 shares outstanding as of March 24, 2026. This disclosure was made via a Schedule 13G/A SEC filing, indicating a passive investment. The filing details shared voting and dispositive power over these shares, held through the Vestal Point Fund and Account.
Bicara Therapeutics (BCAX) executive sells 12,500 shares under plan
Bicara Therapeutics President and COO Ryan Cohlhepp sold 12,500 shares of common stock at a weighted average price of $20.2919 per share and exercised options for 8,000 shares at $3.7898 per share on May 15, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these sales and exercises, Cohlhepp holds 191,641 direct common stock shares and 101,334 stock options.
Bicara Therapeutics president & COO Ryan Cohlhepp sells $253k stock
Bicara Therapeutics President and COO Ryan Cohlhepp sold 12,500 shares of the company's common stock for over $253k on May 15, 2026, while also acquiring 8,000 shares through option exercises. These transactions were executed under a Rule 10b5-1 trading plan. The article also mentions the stock's recent performance, an EPS miss, and analyst ratings from Citizens and Stifel.
Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics has announced an inducement grant to Christopher Sarchi, its new Chief Commercial Officer, under Nasdaq Listing Rule 5635(c)(4). This grant includes a non-qualified stock option to purchase 282,240 shares of common stock at an exercise price of $22.58 per share, vesting over approximately four years. The award serves as a material inducement for his employment, approved by the compensation committee and granted outside of stockholder-approved plans.
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics is progressing with its lead cancer drug candidate, ficerafusp alfa, for head and neck cancer, with pivotal data expected in mid-2026. The drug, a bifunctional antibody targeting EGFR and TGF-beta, has shown promising deep responses, including a 21% complete response rate and significant tumor reductions in clinical data. The company has secured its cash runway into 2029, supporting the ongoing Phase 3 trial, which is currently randomizing patients 2-to-1 to ficerafusp alfa plus pembrolizumab versus pembrolizumab monotherapy, focusing on HPV-negative head and neck cancer.
Bicara Therapeutics Inc. - Common Stock (NQ: BCAX)
This page provides recent news headlines and company updates for Bicara Therapeutics Inc. (NASDAQ: BCAX). Key topics include progress on their lead cancer drug candidate, ficerafusp alfa, ahead of pivotal data in mid-2026, Q1 2026 earnings reports, insider stock transactions, and announcements regarding inducement grants and public offerings. The company is actively involved in clinical development and financial activities to support its therapeutic pipeline.
Number of shareholders of Bicara Therapeutics Inc. – NASDAQ:BCAX
This article provides details on the number of shareholders for Bicara Therapeutics Inc. (NASDAQ: BCAX) and is presented by TradingView. It includes basic financial information, market data, and links to various TradingView products and community features related to stock analysis.
BCAX: Ficerafusp alfa delivers unprecedented durability in head and neck cancer, with pivotal data due mid-2025
Bicara Therapeutics' Ficerafusp alfa is
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to Christopher Sarchi, its new Chief Commercial Officer, effective May 8, 2026. He received stock options for 282,240 shares with an exercise price of $22.58, vesting over four years. This grant was made under Bicara’s 2026 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Bicara Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant in accordance with Nasdaq Listing Rule 5635(c)(4). The biopharmaceutical company is actively developing bifunctional therapies for solid tumors, with its lead program, ficerafusp alfa, targeting EGFR and TGF-b. This news follows several other recent corporate updates for Bicara Therapeutics, including earnings reports and presentations at a major healthcare conference.
New Bicara commercial chief lands option on 282,240 shares
Bicara Therapeutics has granted its new Chief Commercial Officer, Christopher Sarchi, an inducement stock option for 282,240 shares at an exercise price of $22.58. The grant, made under the company's 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), is designed to vest over four years and three months. This aligns Sarchi's incentives with shareholder value and serves as a material inducement for his employment.
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics announced an inducement grant to Christopher Sarchi, its new Chief Commercial Officer, under its 2026 Inducement Plan. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares at $22.58 per share, vesting over approximately four years. This grant was approved by Bicara's compensation committee as a material inducement for his employment, in compliance with Nasdaq Listing Rule 5635(c)(4).
